JSR Life Sciences’ Amsphere A3 Integrated into the Commercial Manufacturing of FDA-Approved Antibody Therapy
SUNNYVALE, California, March 15, 2022 – JSR Life Sciences, LLC today announced that its lead product, Amsphere™ A3 has been incorporated for the first time into the commercial manufacturing of an FDA-approved treatment.
Amsphere™ A3 is a next generation Protein-A chromatography resin that enables advanced protein separation in downstream processing of therapeutic antibodies. Since its launch in January 2016, the product has seen rapid adoption as an alternative option for downstream purification in biologics processing.
“The support provided by our global applications teams really helped make this happen,” said Hideaki Nomura, general manager of JSR Life Sciences’ Bioprocess Division. “Despite international supply chain disruptions affecting most global companies, we are in a position not only to maintain our commitments, but to expand our bioprocess purification materials to support more biologics companies in their pursuit of promising treatments for patients.”
The company is currently expanding on all fronts to facilitate increased manufacturing of biologics. Along with its first commercial launch, Amsphere™ A3 is currently being used in more than 95 clinical programs worldwide.
A business unit of JSR Corporation, JSR Life Sciences, LLC is changing human health as a strategic partner and pathfinder for the life sciences industry. Rooted in a history of materials innovation, JSR Life Sciences provides specialized products, materials, and services to biopharmaceutical companies and academic researchers. Together with its world-class affiliates, JSR Life Sciences offers best-in-class integrated services that de-risk molecule selection, accelerate biologic development timelines, increase clinical success rates, and develop novel in vitro diagnostics. JSR Life Sciences’ global network of affiliates includes Crown Bioscience Inc., KBI Biopharma, Inc., Selexis SA, and MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. The company operates R&D and applications labs, manufacturing facilities, and sales offices worldwide. For more information, visit JSRLifeSciences.com
Contact details
-
- Missy Bindseil
-
JSR Life Sciences Company Inquiries
Director, Marketing & Communications - mbindseil@jsr-nahq.com
-
- Mike Beyer
-
JSR Life Sciences Media Inquiries
Sam Brown Inc. - mikebeyer@sambrown.com
- +1 312-961-2502
Related topics
Related news
KBI Biopharma to Lead Development and Manufacturing of Alanis Therapeutics’ Antagonistic Monoclonal Antibody Candidate
KBI Biopharma Selected as CDMO of Choice to Fast-Track Development of Pre-Clinical Antibody for Blood Cancers Using SUREmAbTM Technology
Prostate Cancer Breakthrough: Crown Bioscience Collaborates in €1.75M Eurostars Funded Project for Novel Liquid Biops...
Crown Bioscience, part of JSR Life Sciences, joins a €1.75M Eurostars project to develop a novel liquid biopsy for prostate cancer, enhancing treatment.
Crown Bioscience Expands Singapore Facility with Advanced Oncology Models and Imaging Capabilities
Crown Bioscience enhances its global presence with the expansion of its Singapore facility, featuring cutting-edge oncology models and imaging capabilities.
JSR Life Sciences to Launch Amsphere™ A+, a Next-Generation Protein A Resin for Antibody Drug Purification
Amsphere™ A+ enhances antibody drug production with advanced polymer technology and high binding capacity, debuting at BPI 2024 and BioJapan.
Crown Bioscience Partners with CTI to Support Consulting Services in Oncology Drug Development
Crown Bioscience announces a strategic partnership with Clinical Trial & Consulting Services (CTI), a renowned global full-spectrum research service provider, to bolster oncology-focused consulting...